[unable to retrieve full-text content]
SALT LAKE CITY, Utah, Jan. 10, 2018 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee (“BRUDAC”) of the U.S. Food and Drug Administration (“FDA”) voted six in favor and…
Powered by WPeMatico
